Company Statements
Biocon Biologics’ New mAbs Facility Receives EU GMP Certification for bBevacizumab
-
Fri, 28-Apr-2023
- Posted by: Biocon Biologics
No Comments
Biocon Biologics Consolidated Statement on USFDA Inspections
-
Wed, 31-Aug-2022
- Posted by: Biocon Biologics
Biocon Statement on Parts of the Charge Sheet Leaked to a Media Outlet
-
Thu, 25-Aug-2022
- Posted by: Biocon Biologics
Biocon Biologics Receives EU GMP Certification for Its New Biologics Manufacturing Facility in Bengaluru
-
Tue, 05-Jul-2022
- Posted by: Biocon Biologics
Biocon Biologics issues a statement in response to the media reports related to bribery allegations
-
Tue, 21-Jun-2022
- Posted by: Biocon Biologics
Biocon Biologics Denies Bribery Allegations
-
Tue, 21-Jun-2022
- Posted by: Biocon Biologics
The USFDA issues a complete response letter for the Biologics License Application (BLA) for insulin Aspart
-
Fri, 07-Jan-2022
- Posted by: Biocon Biologics
Biocon Biologics Insulin Manufacturing Facility in Malaysia Completes U.S. FDA (PAI) Inspection
-
Sat, 25-Sep-2021
- Posted by: Biocon Biologics
Kiran Mazumdar-Shaw Joins Board of Trustees of Memorial Sloan Kettering Cancer Center, U.S.
-
Wed, 28-Apr-2021
- Posted by: Biocon Biologics
Biocon Biologics and Viatris Receive European Commission Approval for Biosimilar Bevacizumab
-
Mon, 26-Apr-2021
- Posted by: Biocon Biologics
